Clinical Trial Search

Primary: Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to the Last Quantifiable Drug Plasma Concentration After Dose Administration (AUC0-tz) of…

Primary: Maximum Observed Plasma Concentration (Cmax) of Bupropion With and Without the Coadministration of ALXN1840 — 98.64; 98.02 nanograms (ng)/milliliter (mL)

Primary: Cmax: Maximum Observed Plasma Concentration for Bismuth — 42.8; 32.9 nanogram per milliliter (ng/mL)

Primary: Maternal Visceral Adipose Tissue Volume — 97593; 169626; 96787 mm3

Primary: Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 2.9 Percentage of total dose

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Part 1 - Number of Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 7; 1; 3; 3 Events

Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: Area Under The Plasma Concentration-Time Curve From Time Zero To 24 Hours (AUC0-24) Postdose Of Oral Doses Of Betrixaban On Day 8 — 437; 807; 1033; 995 ng*h/mL

Primary: Cmax — 698; 715; 755; 680 ng/mL

Primary: Absolute Bioavailability (F) — 105; 54.2; 44.3; 58.2 Percentage of drug

Primary: Percentage of Subjects With Drug-related Adverse Events. — 66.7; 55.6 Percentage of subjects

Primary: Percentage of Patients With Adverse Reactions, Defined as Drug-related Adverse Events (AE) — 57.1 percentage of participants

Primary: Maximum Observed Plasma Concentration (Cmax) Of Celecoxib With And Without The Coadministration Of ALXN1840 — 637.1; 567.4 ng/mL

Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib — 361.1; 370.1; 385.1 nanograms*hours/milliliter…